Skip to main content
. 2020 Apr;9(2):646–653. doi: 10.21037/tau.2019.12.10

Figure 2.

Figure 2

miR-30a-3p inhibits RCC cell invasion and migration in vitro. (A) qRT-PCR assays for miR-30a-3p inhibitors in 786-O and A498 RCC cells versus miR-30a-3p NC cells, respectively. (B) Result of Transwell assay conducted by transfection of miR-30a-3p inhibitors in 786-O and A498 RCC cells versus miR-30a-3p NC cells (crystal violet staining, 200×). (C) Result of wound-healing assays conducted by transfection of miR-30a-3p inhibitors in A498 and 786-O RCC cells versus miR-30a-3p NC cells. (D) qRT-PCR assays for miR-30a-3p mimics in 786-O and A498 RCC cells versus miR-30a-3p NC cells, respectively. (E) Result of Transwell assay conducted by transfection of miR-30a-3p mimics in 786-O and A498 RCC cells versus miR-30a-3p NC cells (crystal violet staining, 200×). (F) Result of wound-healing assays conducted by transfection of miR-30a-3p mimics in A498 and 786-O RCC cells versus miR-30a-3p NC cells. *, P<0.05. RCC, renal cell carcinoma.